Novavax received a $125M milestone payment as Sanofi initiated a Phase 3, combination influenza-COVID-19 vaccine trial in Europe. Future collaboration milestones include an additional $300M upon U.S. launch.
Novavax received a $125M milestone payment as Sanofi initiated a Phase 3, combination influenza-COVID-19 vaccine trial in Europe. Future collaboration milestones include an additional $300M upon U.S. launch.